Rhumbline Advisers Sells 3,110 Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH)

Rhumbline Advisers decreased its holdings in Theravance Biopharma, Inc. (NASDAQ:TBPH) by 4.9% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 59,961 shares of the biopharmaceutical company’s stock after selling 3,110 shares during the quarter. Rhumbline Advisers’ holdings in Theravance Biopharma were worth $564,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also recently modified their holdings of TBPH. Barclays PLC lifted its stake in shares of Theravance Biopharma by 279.9% during the 3rd quarter. Barclays PLC now owns 65,580 shares of the biopharmaceutical company’s stock valued at $529,000 after buying an additional 48,316 shares in the last quarter. JPMorgan Chase & Co. raised its position in Theravance Biopharma by 2.9% during the third quarter. JPMorgan Chase & Co. now owns 266,879 shares of the biopharmaceutical company’s stock valued at $2,151,000 after purchasing an additional 7,620 shares during the period. Algert Global LLC purchased a new position in Theravance Biopharma during the third quarter worth $851,000. Jane Street Group LLC grew its holdings in Theravance Biopharma by 1.1% during the 3rd quarter. Jane Street Group LLC now owns 144,575 shares of the biopharmaceutical company’s stock valued at $1,165,000 after purchasing an additional 1,640 shares during the last quarter. Finally, BNP Paribas Financial Markets boosted its holdings in Theravance Biopharma by 88.9% during the 3rd quarter. BNP Paribas Financial Markets now owns 305,480 shares of the biopharmaceutical company’s stock valued at $2,462,000 after acquiring an additional 143,781 shares during the period. 99.10% of the stock is currently owned by hedge funds and other institutional investors.

Theravance Biopharma Price Performance

Theravance Biopharma stock opened at $9.53 on Friday. The business has a fifty day moving average price of $9.30 and a 200-day moving average price of $8.97. The stock has a market capitalization of $468.63 million, a price-to-earnings ratio of -9.44 and a beta of 0.21. Theravance Biopharma, Inc. has a 1-year low of $7.44 and a 1-year high of $10.90.

Theravance Biopharma (NASDAQ:TBPH) last posted its quarterly earnings results on Wednesday, February 26th. The biopharmaceutical company reported ($0.31) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.26). Theravance Biopharma had a negative return on equity of 24.79% and a negative net margin of 78.18%. The business had revenue of $18.75 million for the quarter, compared to analysts’ expectations of $29.90 million. On average, equities research analysts anticipate that Theravance Biopharma, Inc. will post -1.09 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reaffirmed a “buy” rating and set a $15.00 target price on shares of Theravance Biopharma in a research report on Tuesday, February 25th. Four research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $13.75.

Insider Activity at Theravance Biopharma

In other news, SVP Rhonda Farnum sold 4,000 shares of the business’s stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $9.00, for a total value of $36,000.00. Following the completion of the sale, the senior vice president now directly owns 309,565 shares in the company, valued at $2,786,085. The trade was a 1.28 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 6.90% of the stock is owned by company insiders.

Theravance Biopharma Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.